Filing Details

Accession Number:
0001104659-19-037460
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-25 18:05:51
Reporting Period:
2019-06-24
Accepted Time:
2019-06-25 18:05:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1744659 Akero Therapeutics Inc. AKRO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1727703 Aaron Royston C/o Akero Therapeutics, Inc.
170 Harbor Way, 3Rd Floor
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-06-24 250,000 $16.00 250,000 No 4 P Indirect See Footnote
Common Stock Acquisiton 2019-06-24 3,469,759 $0.00 3,719,759 No 4 C Indirect See Footnote
Common Stock Acquisiton 2019-06-24 235,099 $0.00 3,954,858 No 4 C Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2019-06-24 10,666,667 $0.00 3,469,759 $0.00
Common Stock Series B Preferred Stock Disposition 2019-06-24 722,737 $0.00 235,099 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On June 24, 2019, venBio Global Strategic Fund II, L.P. purchased 250,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.
  2. These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman, Mr. Goodman and Aaron Royston disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
  3. Represents the total number of shares of common stock received by venBio Global Strategic Fund II, L.P. upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
  4. All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
  5. Represents the total number of shares of common stock received by venBio Global Strategic Fund II, L.P. upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.